Heather McArthur, MD, MPH, on Adding Pembrolizumab to Chemotherapy in Early-Stage, High-Risk Breast Cancer

Posted: Tuesday, April 2, 2024

Heather McArthur, MD, MPH, of UT Southwestern Medical Center, discusses her findings from the KEYNOTE-756 trial, which focused on patients with early-stage, high-risk estrogen receptor–positive or HER2-negative breast cancer who may benefit from adding pembrolizumab to neoadjuvant chemotherapy.

---